Kenjockety Biotechnology Reports Preclinical Results for Tumor-Focused, Bispecific Antibody (BsAb) Targeting P-Glycoprotein (Pgp) and CD47 at SITC 2021 (Abstract 282)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kenjockety Biotechnology, Inc. to present new data on their lead bispecific antibody (BsAb) program targeting Pgp and CD47 at SITC Annual Meeting.

Click to view original post